EA200701582A1 - Замещённые 5-фенилпиримидины i в терапии - Google Patents

Замещённые 5-фенилпиримидины i в терапии

Info

Publication number
EA200701582A1
EA200701582A1 EA200701582A EA200701582A EA200701582A1 EA 200701582 A1 EA200701582 A1 EA 200701582A1 EA 200701582 A EA200701582 A EA 200701582A EA 200701582 A EA200701582 A EA 200701582A EA 200701582 A1 EA200701582 A1 EA 200701582A1
Authority
EA
Eurasian Patent Office
Prior art keywords
radical
radicals
carry
alkyl
ring
Prior art date
Application number
EA200701582A
Other languages
English (en)
Other versions
EA014098B1 (ru
Inventor
Йоахим Райнхаймер
Томас Гротэ
Бернд МЮЛЛЕР
Барбара Наве
Франк Шивек
Анья Швеглер
Торстен Ябс
Карстен Блеттнер
Original Assignee
Басф Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Басф Акциенгезелльшафт filed Critical Басф Акциенгезелльшафт
Publication of EA200701582A1 publication Critical patent/EA200701582A1/ru
Publication of EA014098B1 publication Critical patent/EA014098B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к замещенным 5-фенилпиримидинам формулы I, которые несут радикал Х в 4-й позиции пиримидинового кольца, радикал Y в 6-й позиции пиримидинового кольца, где Х означает одну из групп с формулой NRR, ORили SR, в которых R, R, независимо друг от друга, означают водород, C-С-алкил, С-С-алкенил, С-С-алкинил, C-С-галоалкил, С-С-циклоалкил, С-С-галоциклоалкил, фенил, или 5- или 6-членный гетероарил или 5- или 6-членный гетероциклил, содержащий 1, 2, 3 или 4 атома азота или 1, 2 или 3 атома азота и один атом серы или кислорода в качестве членов кольца, радикалы в котором могут быть незамещенными или могут нести 1, 2, 3 или 4 радикала R; или радикал NRRможет также формировать 5- или 6-членное, необязательно замещенное гетероциклическое кольцо, содержащее 1, 2, 3 или 4 атома азота или 1, 2 или 3 атома азота и один атом серы или кислорода в качестве членов кольца, которые не являются соседними с азотом из NRR, в котором два соседних атома углерода или один атом азота и один соседний атом углерода могут быть связаны С-С-алкиленовой цепью и где гетероциклическое кольцо может быть незамещенным или может нести 1,2,3 или 4 радикала R, как указано в п.1, Rимеет одно из значений, данных для R, кроме водорода; радикал Y выбирается из группы, состоящей из галогена, циано, С-С-алкила, С-С-алкенила, С-С-алкинила, С-С-циклоалкила, С-С-алкокси, С-С-алкенилокси, С-С-алкинилокси, C-С-алкилтио, ди(С-С-алкил)амино или C-С-алкиламино, где алкил, алкенил или алкинил радикалы Y могут быть замещены галогеном, циано, нитро, C-C-алкокси или С-С-алкоксикарбонилом; и где пиримидиновый радикал может также во 2-й позиции нести радикал, отличный от водорода, и где фенильное кольцо в 5-й позиции пиримидинового кольца может быть незамещенным или нести 1, 2, 3, 4 или 5 радикалов L, отличных от
EA200701582A 2005-01-31 2006-01-30 Замещённые 5-фенилпиримидины в терапии рака, фармацевтическая композиция на их основе и способ лечения рака у животных EA014098B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05001955 2005-01-31
PCT/EP2006/000774 WO2006079556A2 (en) 2005-01-31 2006-01-30 Substituted 5-phenyl pyrimidines i in therapy

Publications (2)

Publication Number Publication Date
EA200701582A1 true EA200701582A1 (ru) 2008-02-28
EA014098B1 EA014098B1 (ru) 2010-08-30

Family

ID=34933530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701582A EA014098B1 (ru) 2005-01-31 2006-01-30 Замещённые 5-фенилпиримидины в терапии рака, фармацевтическая композиция на их основе и способ лечения рака у животных

Country Status (19)

Country Link
US (1) US20080146593A1 (ru)
EP (1) EP1845991A2 (ru)
JP (1) JP2008528535A (ru)
KR (1) KR20070104893A (ru)
CN (1) CN101111250A (ru)
AR (1) AR054220A1 (ru)
AU (1) AU2006208621B2 (ru)
BR (1) BRPI0607108A2 (ru)
CA (1) CA2595958A1 (ru)
EA (1) EA014098B1 (ru)
IL (1) IL184375A0 (ru)
MX (1) MX2007008397A (ru)
NZ (1) NZ556448A (ru)
PE (1) PE20061042A1 (ru)
TW (1) TW200637556A (ru)
UA (1) UA87895C2 (ru)
UY (1) UY29352A1 (ru)
WO (1) WO2006079556A2 (ru)
ZA (1) ZA200707315B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144140A1 (en) * 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
TW200836741A (en) * 2007-01-11 2008-09-16 Basf Ag 2-substituted pyrimidines I in therapy
KR100936278B1 (ko) * 2007-12-14 2010-01-13 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물
AU2009282567B2 (en) * 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
CN111065635B (zh) * 2018-01-04 2022-07-22 无锡安万生物科技有限公司 作为mth1抑制剂的新型嘧啶衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006235A (en) * 1973-03-23 1977-02-01 Burroughs Wellcome Co. Treating CNS lymphoma
GB8314643D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Pyrimidine derivatives
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9700664D0 (en) * 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
BR0207975A (pt) * 2001-03-15 2004-06-15 Basf Ag Composto, processo para preparar 5 fenilpiridinas, produto intermediário, agente adequado para combater fungos nocivos fitopatogênicos, e, processo para combater fungos nocivos fitopatogênicos
US6887875B2 (en) * 2001-06-12 2005-05-03 Neurogen Corporation 2,5-diarypyrimidine compounds
IL161893A0 (en) * 2001-11-19 2005-11-20 Basf Ag 5-Phenylpyrimidines, agents comprising the same, method for production and use thereof
ATE428705T1 (de) * 2002-02-21 2009-05-15 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
AU2003249484A1 (en) * 2002-07-22 2004-02-09 Orchid Chemicals And Pharmaceuticals Ltd Novel bio-active molecules
US7371758B2 (en) * 2003-03-13 2008-05-13 National Science & Technology Development Agency Antimalarial pyrimidine derivatives and methods of making and using them
US20070054929A1 (en) 2003-05-20 2007-03-08 Basf Aktiengesellschaft 2-Substituted pyrimidines
CA2532568A1 (en) * 2003-07-24 2005-03-03 Basf Aktiengesellschaft 2-substituted pyrimidines
JP2007506746A (ja) * 2003-09-24 2007-03-22 ワイス・ホールディングズ・コーポレイション 抗癌剤としての5−アリールピリミジン類
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
DE102004003493A1 (de) * 2004-01-23 2005-08-11 Bayer Cropscience Ag 5-Phenylpyrimidine
JP2008505957A (ja) * 2004-07-14 2008-02-28 ビーエーエスエフ アクチェンゲゼルシャフト 2−置換ピリミジン、その調製方法および有害菌類を防除するためのその使用

Also Published As

Publication number Publication date
EP1845991A2 (en) 2007-10-24
EA014098B1 (ru) 2010-08-30
BRPI0607108A2 (pt) 2010-03-09
KR20070104893A (ko) 2007-10-29
TW200637556A (en) 2006-11-01
WO2006079556A2 (en) 2006-08-03
WO2006079556A3 (en) 2006-09-21
JP2008528535A (ja) 2008-07-31
IL184375A0 (en) 2007-10-31
CA2595958A1 (en) 2006-08-03
AU2006208621B2 (en) 2011-08-11
ZA200707315B (en) 2008-11-26
UA87895C2 (en) 2009-08-25
CN101111250A (zh) 2008-01-23
MX2007008397A (es) 2007-09-07
AU2006208621A1 (en) 2006-08-03
UY29352A1 (es) 2006-08-31
US20080146593A1 (en) 2008-06-19
PE20061042A1 (es) 2006-11-20
NZ556448A (en) 2010-12-24
AR054220A1 (es) 2007-06-13

Similar Documents

Publication Publication Date Title
TW200635585A (en) Monocyclic substituted methanones
TW200615267A (en) New bicyclic antibiotics
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
NZ587926A (en) Pyridines and pyrazines as inhibitors of pi3k
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
NO20066015L (no) Fuserte heterosykliske forbindelser
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
TW200633991A (en) Chemical compounds
EA200602022A1 (ru) Фунгицидные смеси
MX2009010309A (es) Bases nitrogenadas fotoactivables.
EA200701582A1 (ru) Замещённые 5-фенилпиримидины i в терапии
EA200970379A1 (ru) Бициклические гетероароматические соединения
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
EA201000101A1 (ru) Производные пиримидина 934
TW200612920A (en) Novel imidazolidine derivatives
MY145066A (en) Methods for treating sexual dysfunction
NO20064175L (no) Heterosyklisk forbindelse
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
EA200971063A1 (ru) Ариламидпиримидоновые соединения
NO873650D0 (no) Dihydropyridinderivater.
MY146939A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY MD RU